Rationale for use of dopamine agonists in Parkinson's disease: Review of ergot derivatives

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Blanchet, Pierre J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; LISURIDE MALEATE; PERGOLIDE MESILATE; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR;

COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HALLUCINATION; HUMAN; HYPOTENSION; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VERTIGO;

EID: 0032805905     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000056     Document Type: Review

References (91)

1. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-Dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8: 129-133.
2. Fukuda T, Watabe K, Tanaka J. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996; 728: 274-276.
3. Agid Y. Levodopa - Is toxicity a myth? Neurology 1998; 50: 858-863.
4. Trabucchi M, Spano PF, Tonon GC, Frattola L. Effects of bromocriptine on central dopaminergic receptors. Life Sci 1976; 19: 225-232.
5. Markstein R, Herrling PL, Bürki HR, Asper H, Ruch W. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem 1978; 31: 1163-1172.
6. 3H]spiperone binding and dopamine-stimulated cyclic AMP formation. Naunyn-Schmied Arch Pharmacol 1978; 304: 141-145.
7. Gopinathan G, Horowski R, Suchy IH. Lisuride pharmacology and treatment of Parkinson's disease. In: Calne DB, ed. Drugs for the Treatment of Parkinson's Disease. Berlin Heidelberg: Springer-Verlag, 1989; chap 19, 471-513.
8. 2 agonist with antiparkinsonian properties - preclinical studies. Ann Neurol 1991; 30: 258.
9. Goldstein M, Lieberman A, Lew JY, et al. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 1980; 77: 3725-3728.
10. Andersen PH, Jansen JA. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol - Molec Pharmacol Sect 1990; 188: 335-347.
11. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm [P-D Sect] 1991; 3: 151-201.
12. 3 dopamine receptors in human striatum. Prog Neuro-Psychopharmacol & Biol Psychiat 1995; 19: 1147-1154.
13. Gershanik O, Heikkila RE, Duvoisin RC. Behavioral correlations of dopamine receptor activation. Neurology 1983; 33: 1489-1492.
14. 1 and D2 dopamine receptors appears necessary for full expression of postsynaptic effects of dopamine agonists: a neurophysiological study. Brain Res 1987; 400: 205-218.
15. 2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat. Neuropharmacology 1988; 27: 1257-1264.
16. Robertson HA. Synergistic interactions of D1-and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias. Can J Neurol Sci 1992; 19: 147-152.
17. Gomez-Mancilla B, Boucher R, Gagnon C, et al. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov Disord 1993; 8: 144-150.
18. Vermeulen RJ, Drukarch B, Sahadat MCR, et al. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 1994; 9: 664-672.
19. Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 1988; 156: 197-206.
20. Taylor JR, Lawrence MS, Redmond DE Jr, et al. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991; 199: 389-391.
21. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Therap 1993; 267: 275-279.
22. Temlett JA, Quinn NP, Jenner PG, et al. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 1989; 4: 261-265.
23. Rascol O, Blin O, Descombes S, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 1997; 48: A269-A270.
24. Blanchet PJ, Fang J, Gillespie M, et al. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol (in press).
25. Sautel F, Griffon N, Lévesque D, et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport 1995; 6: 329-332.
26. Eisler T, Hall RP, Kalavar KAR, Calne DB. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 1981; 31: 1368-1370.
27. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988; 148: 2231-2236.
28. 3H]spiperone binding. Brain Res 1986; 379: 294-299.
29. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S, eds. Advances in Neurology, vol 69: Drugs for the Treatment of Parkinson's Disease. Philadelphia: Lippincott-Raven, 1996: 62, 497-501.
30. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990; 27: 18-23.
31. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992; 32: 776-781.
32. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113-118.
33. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473-478.
34. Soghomonian J-J, Pedneault S, Blanchet PJ, et al. L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys. Mol Brain Res 1996; 39: 237-240.
35. Morissette M, Goulet M, Soghomonian J-J, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Mol Brain Res 1997; 49: 55-62.
36. Doucet J-P, Nakabeppu Y, Bédard PJ, et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of FosB-like protein(s) in both rodent and primate striatum. Eur J Neurosci 1996; 8: 365-381.
37. A receptors in the striatopallidal complex. Brain Res 1995; 680: 43-52.
38. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989; 168: 291-298.
39. Blanchet PJ, Gomez-Mancilla B, Bédard PJ. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J Neural Transm 1995; 45(Suppl): 103-112.
40. Gagnon C, Bédard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990; 178: 115-120.
41. Grondin R, Bédard PJ. Cabergoline: a promising agent for the treatment of Parkinson's disease. CNS Drug Rev 1996; 2: 214-225.
42. Bédard PJ, Gomez-Mancilla B, Blanchet P, et al. Role of selective D-1 and D-2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in Neurology, Vol 60: From Basic Research to Treatment. New York: Raven Press, 1993, chap 16, 113-118.
43. Blanchet PJ, Grondin R, Bédard PJ. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned primates. Mov Disord 1996; 11: 91-94.
44. Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 1996; 719: 129-137.
45. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2: 73-91.
46. Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984; 11(Suppl): 160-165.
47. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. In: Yahr MD, Bergman KJ, eds. Advances in Neurology, Vol 45: Parkinson's Disease. New York: Raven Press, 1986, 463-467.
48. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol 1997; 37: 23-27.
49. Clarke CE, Boyce S, Sambrook MA, Crossman AR. Timing of levodopa therapy: evidence from MPTP-treated primates. Lancet 1987; 1: 625.
50. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34: 193-196.
51. Blanchet PJ, Allard P, Grégoire L, Tardif F, Bédard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-193.
52. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979; 42: 143-150.
53. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44: 1020-1023.
54. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand 1990; 81: 383-387.
55. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-1038.
56. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-910.
57. Yanagisawa N, Kanazawa I, Goto I, et al. Seven-year follow-up study of bromocriptine therapy for Parkinson's disease. Eur Neurol 1994; 34(Suppl 3): 29-35.
58. Riopelle RJ, Gawel M, Libman I, et al. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease: results of six months. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease, Vol II. Florham Park: Macmillan Healthcare Information, 1987, 215-219.
59. Olanow CW, Alberts MJ, Stajich J, Burch G. A randomized blinded study of low-dose bromocriptine versus low-dose carbidopa/levodopa in untreated Parkinson's patients. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease, Vol II. Florham Park: Macmillan Healthcare Information, 1987, 201-208.
60. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993; 307: 469-472.
61. Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1979; 1: 570-572.
62. Mear J-Y, Barroche G, de Smet Y, et al. Pergolide in the treatment of Parkinson's disease. Neurology 1984; 34: 983-986.
63. Lieberman A, Goldstein M, Neophytides A, et al. Lisuride in Parkinson's disease: efficacy of lisuride compared with levodopa. Neurology 1981; 31: 961-965.
64. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997; 48: 363-368.
65. Runge I, Horowski R. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl. J Neural Transm [P-D Sect] 1991; 4: 273-283.
66. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506.
67. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994; 51: 1236-1241.
68. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985; 35: 1196-1198.
69. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-828.
70. Giménez-Roldán S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997; 20: 67-76.
71. Przuntek H, Welzel D, Blümner E, et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 1992; 43: 357-363.
72. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8: 257-262.
73. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991-996.
74. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36: 1528-1530.
75. Lieberman AN, Gopinathan G, Hassouri H, Neophytides A, Goldstein M. Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine. Can J Neurol Sci 1984; 11: 233-237.
76. Grimes JD. Bromocriptine in Parkinson's disease: results obtained with high and low dose therapy. Can J Neurol Sci 1984; 11: 225-228.
77. Lieberman AN, Gopinathan G, Neophytides A, Goldstein M. Management of levodopa failures: the use of dopamine agonists. Clin Neuropharmacol 1986; 9: S9-S21.
78. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease. Mov Disord 1994; 9: 40-47.
79. Ahlskog JE, Muenter MD. Pergolide: long-term use in Parkinson's disease. Mayo Clin Proc 1988; 63: 979-987.
80. Tanner CM, Goetz CG, Glantz RH, Klawans HL. Pergolide mesylate: four years experience in Parkinson's disease. In: Yahr MD, Bergman KJ, eds. Advances in Neurology, Vol 45: Parkinson's Disease. New York: Raven Press, 1986, 547-549.
81. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996; 11: 327-341.
82. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988; 51: 529-533.
83. Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749-751.
84. Lieberman AN, Goldstein M. Treatment of advanced Parkinson's disease with dopamine agonists. In: Marsden CD, Fahn S, eds. Movement Disorders, Vol 2. London: Butterworth & Co (Publishers) Ltd, 1981: 146-165.
85. Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A. Lisuride in parkinsonism. Ann Neurol 1981; 9: 48-52.
86. Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990; 28: 593-594.
87. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992; 13: 339-351.
88. Lange KW, Rausch W-D, Gsell W, et al. Neuroprotection by dopamine agonists. J Neural Transm 1994; 43(Suppl): 183-201.
89. Ogawa N, Tanaka K-i, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207-213.
90. Lichter D, Kurlan R, Miller C, Shoulson I. Does pergolide slow the progression of Parkinson's disease? A 7-year follow-up study. Neurology 1988; 38(Suppl 1): 122.
91. Zimmerman T, Sage JI. Comparison of combination pergolide and levodopa to levodopa alone after 63 months of treatment. Clin Neuropharmacol 1991; 14: 165-169.